Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 61023L207 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Janus Henderson Group PLC
13G/A
|
19.5% |
11/14/2025
Event 9/30/2025
|
||
| Janus Henderson Group PLC | 19.5% | |||
| Janus Henderson Biotech Innovation Master Fund Ltd | 16.7% | |||
|
Monopar Therapeutics
13D/A
|
13.4% |
2/7/2025
Event 12/9/2024
|
||
| Monopar Therapeutics | 11.6% | |||
| Hendricks Diane | 13.4% | |||
| Leo Karl | 13.4% | |||
| Pharma Investments LLC | 11.6% | |||
|
RA Capital Management, L.P.
13G/A
|
9.9% |
2/17/2026
Event 12/31/2025
|
||
| RA Capital Management, L.P. | 9.9% | |||
| Peter Kolchinsky | 9.9% | |||
| Rajeev Shah | 9.9% | |||
| RA Capital Healthcare Fund, L.P. | 9.9% | |||
|
AstraZeneca PLC
13G/A
|
7.8% |
2/6/2026
Event 12/31/2025
|
||
| AstraZeneca PLC | 7.8% | |||
| Alexion Pharmaceuticals, Inc. | 7.8% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (4) | ||||
|
Adage Capital Management, L.P.
13G/A
|
4.8% |
8/12/2026
Event 6/30/2026
|
||
| Adage Capital Management, L.P. | 4.8% | |||
| Robert Atchinson | 4.8% | |||
| Phillip Gross | 4.8% | |||
|
Saturn V Capital Management LP
13G/A
|
4.7% |
8/12/2026
Event 6/30/2026
|
||
| Saturn V Capital Management LP | 4.7% | |||
| Xiaoying Tian | 4.7% | |||
|
Tactic Pharma LLC
13D/A
|
4.5% |
1/30/2026
Event 1/28/2026
|
||
| Tactic Pharma LLC | 0% | |||
| Robinson Chandler | 4.5% | |||
| Brown Michael J | 1.8% | |||
|
Tang Capital Management LLC
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Tang Capital Management, LLC | 0% | |||
| Kevin Tang | 0% | |||
| Tang Capital Partners, LP | 0% | |||
| Tang Capital Partners III, Inc | 0% | |||
| Tang Capital Partners IV, Inc | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 66.0 | $5.26 k |
| 2026 Q2 | 97 | 6.23 M | $576 M |
| 2026 Q1 | 83 | 6.24 M | $342 M |
| 2025 Q4 | 76 | 5.53 M | $361 M |
| 2025 Q3 | 57 | 4.34 M | $354 M |
| 2025 Q2 | 45 | 3.18 M | $113 M |
| 2025 Q1 | 36 | 2.89 M | $109 M |
| 2024 Q4 | 19 | 2.58 M | $57.1 M |
| 2024 Q3 | 7 | 15.7 k | $106 k |